Royalty Pharma (RPRX) reported Q4 net income Tuesday of $208 million, down from $494 million a year earlier.
Comparable analyst estimates were not available.
Total income and other revenues ended Dec. 31 were $594 million, down from $596 million a year earlier.
Analysts surveyed by FactSet expected $687 million.
As of Dec. 31, the company said it had $929 million in cash and cash equivalents.
Shares of the UK biopharmaceutical company were up more than 2% in Tuesday's premarket activity.
Price: 32.45, Change: +0.73, Percent Change: +2.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。